AbCellera Biologics (ABCL) Financials

$2.43 -0.01 (-0.41%)

Closing price 04/15/2025 04:00 PM Eastern

Extended Trading

$2.41 -0.02 (-0.82%)

As of 09:07 AM Eastern

Annual Income Statements for AbCellera Biologics

This table shows AbCellera Biologics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	159	-146	-163
Consolidated Net Income / (Loss)	159	-146	-163
Net Income / (Loss) Continuing Operations	159	-146	-163
Total Pre-Tax Income	239	-174	-200
Total Operating Income	217	-237	-315
Total Gross Profit	485	38	29
Total Revenue	485	38	29
Operating Revenue	485	38	29
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	269	275	344
Selling, General & Admin Expense	55	61	73
Marketing Expense	11	14	13
Research & Development Expense	108	176	167
Depreciation Expense	28	24	91
Other Operating Expenses / (Income)	66	0.00	0.00
Total Other Income / (Expense), net	23	63	114
Interest & Investment Income	16	42	38
Other Income / (Expense), net	6.51	21	76
Income Tax Expense	81	-28	-38
Basic Earnings per Share	$0.56	($0.51)	($0.55)
Weighted Average Basic Shares Outstanding	285.06M	289.17M	294.33M
Diluted Earnings per Share	$0.50	($0.51)	($0.55)
Weighted Average Diluted Shares Outstanding	314.83M	289.17M	294.33M
Weighted Average Basic & Diluted Shares Outstanding	287.69M	292.78M	297.99M

This table shows AbCellera Biologics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	27	-30	-40	-30	-28	-48	-41	-37	-50	-35
Consolidated Net Income / (Loss)	27	-30	-40	-31	-29	-47	-41	-37	-51	-34
Net Income / (Loss) Continuing Operations	27	-30	-40	-31	-29	-47	-41	-37	-51	-34
Total Pre-Tax Income	47	-31	-48	-38	-39	-49	-43	-48	-63	-47
Total Operating Income	38	-38	-65	-51	-55	-66	-55	-93	-94	-73
Total Gross Profit	101	22	12	10	6.60	9.18	9.95	7.32	6.51	5.05
Total Revenue	101	22	12	10	6.60	9.18	9.95	7.32	6.51	5.05
Operating Revenue	101	22	12	10	6.60	9.18	9.95	7.32	6.51	5.05
Total Operating Expenses	64	59	77	61	61	75	65	101	100	78
Selling, General & Admin Expense	14	13	15	16	14	16	17	20	19	16
Marketing Expense	3.09	2.69	3.77	3.84	3.47	3.10	3.37	3.14	3.14	3.14
Research & Development Expense	27	28	53	36	38	49	39	41	41	46
Depreciation Expense	5.15	14	5.51	5.61	5.74	7.54	4.84	37	37	13
Total Other Income / (Expense), net	8.85	6.37	17	13	16	17	12	45	31	26
Interest & Investment Income	5.56	8.44	9.76	11	11	11	10	9.80	9.60	8.67
Other Income / (Expense), net	3.30	-2.08	6.97	2.61	4.87	6.48	1.75	35	21	17
Income Tax Expense	20	-1.52	-8.04	-7.48	-11	-1.45	-2.14	-11	-12	-13
Basic Earnings per Share	$0.09	($0.10)	($0.14)	($0.11)	($0.10)	($0.16)	($0.14)	($0.13)	($0.17)	($0.11)
Weighted Average Basic Shares Outstanding	285.32M	285.06M	287.77M	288.91M	289.50M	289.17M	292.72M	294.22M	294.85M	294.33M
Diluted Earnings per Share	$0.08	($0.10)	($0.14)	($0.11)	($0.10)	($0.16)	($0.14)	($0.13)	($0.17)	($0.11)
Weighted Average Diluted Shares Outstanding	315.82M	314.83M	287.77M	288.91M	289.50M	289.17M	292.72M	294.22M	294.85M	294.33M
Weighted Average Basic & Diluted Shares Outstanding	286.10M	287.69M	288.73M	289.36M	290.17M	292.78M	294.05M	294.67M	295.37M	297.99M

This table details how cash moves in and out of AbCellera Biologics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	-86	-254	23
Net Cash From Operating Activities	277	-44	-109
Net Cash From Continuing Operating Activities	277	-44	-109
Net Income / (Loss) Continuing Operations	159	-146	-163
Consolidated Net Income / (Loss)	159	-146	-163
Depreciation Expense	8.95	13	13
Amortization Expense	24	18	84
Non-Cash Adjustments To Reconcile Net Income	56	58	-17
Changes in Operating Assets and Liabilities, net	30	13	-26
Net Cash From Investing Activities	-353	-221	121
Net Cash From Continuing Investing Activities	-353	-221	121
Purchase of Property, Plant & Equipment	-71	-77	-78
Acquisitions	-28	-14	-20
Purchase of Investments	-781	-1,066	-754
Sale and/or Maturity of Investments	511	911	938
Other Investing Activities, net	16	25	36
Net Cash From Financing Activities	-1.63	10	13
Net Cash From Continuing Financing Activities	-1.63	10	13
Other Financing Activities, net	-1.63	10	13
Effect of Exchange Rate Changes	-9.60	0.59	-2.62

This table details how cash moves in and out of AbCellera Biologics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-417	15	-194	-13	-7.33	-39	-9.75	25	-22	30
Net Cash From Operating Activities	-127	31	-44	20	-0.11	-20	-42	-30	-29	-8.00
Net Cash From Continuing Operating Activities	-127	31	-44	20	-0.11	-20	-42	-30	-29	-8.00
Net Income / (Loss) Continuing Operations	27	-30	-40	-31	-29	-47	-41	-37	-51	-34
Consolidated Net Income / (Loss)	27	-30	-40	-31	-29	-47	-41	-37	-51	-34
Depreciation Expense	2.53	2.74	2.86	2.95	3.06	3.88	3.16	3.45	3.83	2.10
Amortization Expense	4.20	13	4.26	4.30	4.35	5.23	3.61	35	34	12
Non-Cash Adjustments To Reconcile Net Income	15	16	12	16	20	11	19	-23	7.55	-20
Changes in Operating Assets and Liabilities, net	-175	29	-23	28	0.80	7.76	-27	-8.04	-24	33
Net Cash From Investing Activities	-282	-17	-150	-34	-13	-24	30	52	3.70	36
Net Cash From Continuing Investing Activities	-282	-17	-150	-34	-13	-24	30	52	3.70	36
Purchase of Property, Plant & Equipment	-13	-12	-15	-27	-20	-14	-24	-20	-19	-16
Acquisitions	-6.08	-5.91	-4.47	-2.20	-3.54	-4.04	-5.91	-4.91	-7.14	-1.67
Purchase of Investments	-542	-94	-395	-170	-216	-284	-254	-168	-177	-155
Sale and/or Maturity of Investments	272	92	263	160	220	268	307	233	197	202
Other Investing Activities, net	6.00	2.33	2.69	5.00	7.33	10	7.17	13	9.40	6.56
Net Cash From Financing Activities	-0.02	0.35	-0.46	0.42	6.63	3.77	2.83	2.65	3.15	4.14
Net Cash From Continuing Financing Activities	-0.02	0.35	-0.46	0.42	6.63	3.77	2.83	2.65	3.15	4.14
Other Financing Activities, net	-0.25	2.76	-0.46	0.42	0.07	10	0.71	0.28	0.04	12
Effect of Exchange Rate Changes	-8.55	0.36	-0.21	0.80	-1.06	1.07	-0.78	-0.04	0.37	-2.16

This table presents AbCellera Biologics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	1,541	1,488	1,361
Total Current Assets	1,025	872	751
Cash & Equivalents	387	133	156
Restricted Cash	25	25	25
Short-Term Investments	500	627	469
Accounts Receivable	39	31	34
Other Current Assets	75	56	67
Plant, Property, & Equipment, net	0.00	0.00	0.00
Total Noncurrent Assets	515	616	609
Long-Term Investments	73	66	82
Goodwill	48	48	48
Intangible Assets	132	120	42
Other Noncurrent Operating Assets	264	382	437
Total Liabilities & Shareholders' Equity	1,541	1,488	1,361
Total Liabilities	308	336	304
Total Current Liabilities	118	119	77
Short-Term Debt	44	50	8.09
Accounts Payable	52	50	55
Current Deferred Revenue	22	19	14
Total Noncurrent Liabilities	189	217	228
Noncurrent Deferred Revenue	20	8.20	5.70
Noncurrent Deferred & Payable Income Tax Liabilities	33	31	10
Other Noncurrent Operating Liabilities	137	178	212
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,233	1,152	1,056
Total Preferred & Common Equity	1,233	1,152	1,056
Total Common Equity	1,233	1,152	1,056
Common Stock	808	874	944
Retained Earnings	426	280	117
Accumulated Other Comprehensive Income / (Loss)	-1.39	-1.72	-4.38

This table presents AbCellera Biologics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	1,552	1,498	1,537	1,512	1,463	1,412	1,393
Total Current Assets	1,046	941	931	920	814	772	743
Cash & Equivalents	372	193	180	172	124	148	127
Restricted Cash	25	25	25	25	25	25	25
Short-Term Investments	496	603	616	613	574	522	516
Accounts Receivable	106	20	46	37	34	36	31
Other Current Assets	46	99	64	71	57	40	43
Plant, Property, & Equipment, net	201	233	260	277	0.00	0.00	0.00
Total Noncurrent Assets	306	324	347	315	649	641	650
Long-Term Investments	67	58	59	63	72	76	84
Goodwill	48	48	48	48	48	48	48
Intangible Assets	143	129	127	124	119	86	53
Other Noncurrent Operating Assets	49	90	113	81	411	431	465
Total Liabilities & Shareholders' Equity	1,552	1,498	1,537	1,512	1,463	1,412	1,393
Total Liabilities	302	289	342	329	333	302	315
Total Current Liabilities	106	90	119	110	105	70	80
Short-Term Debt	33	43	55	54	51	20	20
Accounts Payable	26	32	52	36	43	44	54
Current Deferred Revenue	6.82	12	8.54	18	11	6.40	5.58
Total Noncurrent Liabilities	196	200	223	219	228	231	235
Noncurrent Deferred Revenue	-	25	28	16	8.57	7.97	8.10
Noncurrent Deferred & Payable Income Tax Liabilities	34	33	33	33	30	22	13
Other Noncurrent Operating Liabilities	162	141	163	170	189	201	214
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,250	1,209	1,195	1,183	1,130	1,111	1,078
Total Preferred & Common Equity	1,250	1,209	1,195	1,183	1,130	1,111	1,078
Total Common Equity	1,250	1,209	1,195	1,183	1,130	1,111	1,078
Common Stock	795	824	841	857	893	911	928
Retained Earnings	456	386	356	327	239	202	151
Accumulated Other Comprehensive Income / (Loss)	-0.72	-2.02	-1.90	-1.46	-1.82	-2.07	-1.23

This table displays calculated financial ratios and metrics derived from AbCellera Biologics' official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	29.38%	-92.17%	-24.17%
EBITDA Growth	9.89%	-172.38%	23.47%
EBIT Growth	3.34%	-196.98%	-10.45%
NOPAT Growth	0.28%	-215.68%	-32.70%
Net Income Growth	3.29%	-192.35%	-11.24%
EPS Growth	4.17%	-202.00%	-7.84%
Operating Cash Flow Growth	13.40%	-115.82%	-147.41%
Free Cash Flow Firm Growth	-18.56%	-322.85%	10.50%
Invested Capital Growth	17.22%	19.69%	-5.70%
Revenue Q/Q Growth	-19.52%	-24.54%	-12.53%
EBITDA Q/Q Growth	-30.18%	-16.29%	5.88%
EBIT Q/Q Growth	-35.22%	-10.03%	1.68%
NOPAT Q/Q Growth	-38.85%	-13.53%	-2.18%
Net Income Q/Q Growth	-36.17%	-13.36%	7.36%
EPS Q/Q Growth	-37.50%	-13.33%	8.33%
Operating Cash Flow Q/Q Growth	20.73%	-760.20%	9.66%
Free Cash Flow Firm Q/Q Growth	31.28%	-20.05%	-0.79%
Invested Capital Q/Q Growth	-9.08%	-3.23%	-4.28%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	52.76%	-487.53%	-492.04%
Operating Margin	44.60%	-623.82%	-1,091.69%
EBIT Margin	45.94%	-568.77%	-828.45%
Profit (Net Income) Margin	32.66%	-385.00%	-564.83%
Tax Burden Percent	66.30%	84.12%	81.27%
Interest Burden Percent	107.21%	80.47%	83.89%
Effective Tax Rate	33.70%	0.00%	0.00%
Return on Invested Capital (ROIC)	52.79%	-51.51%	-64.56%
ROIC Less NNEP Spread (ROIC-NNEP)	51.04%	-53.76%	-72.10%
Return on Net Nonoperating Assets (RNNOA)	-38.75%	39.23%	49.82%
Return on Equity (ROE)	14.03%	-12.27%	-14.75%
Cash Return on Invested Capital (CROIC)	36.94%	-69.43%	-58.70%
Operating Return on Assets (OROA)	15.60%	-14.28%	-16.77%
Return on Assets (ROA)	11.09%	-9.67%	-11.43%
Return on Common Equity (ROCE)	14.03%	-12.27%	-14.75%
Return on Equity Simple (ROE_SIMPLE)	12.85%	-12.70%	-15.42%
Net Operating Profit after Tax (NOPAT)	144	-166	-220
NOPAT Margin	29.57%	-436.67%	-764.18%
Net Nonoperating Expense Percent (NNEP)	1.75%	2.26%	7.53%
Return On Investment Capital (ROIC_SIMPLE)	11.24%	-13.80%	-20.71%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	11.43%	160.42%	252.18%
R&D to Revenue	22.22%	461.95%	580.10%
Operating Expenses to Revenue	55.40%	723.82%	1,191.69%
Earnings before Interest and Taxes (EBIT)	223	-216	-239
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	256	-185	-142
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.35	1.44	0.82
Price to Tangible Book Value (P/TBV)	2.75	1.68	0.90
Price to Revenue (P/Rev)	5.97	43.57	30.02
Price to Earnings (P/E)	18.28	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	5.47%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	6.67	2.44	0.42
Enterprise Value to Revenue (EV/Rev)	4.03	22.51	4.88
Enterprise Value to EBITDA (EV/EBITDA)	7.65	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	8.78	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	13.64	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	7.06	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	19.50	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.04	0.04	0.01
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.76	-0.73	-0.69
Leverage Ratio	1.27	1.27	1.29
Compound Leverage Factor	1.36	1.02	1.08
Debt to Total Capital	3.46%	4.20%	0.76%
Short-Term Debt to Total Capital	3.46%	4.20%	0.76%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	96.54%	95.80%	99.24%
Debt to EBITDA	0.17	-0.27	-0.06
Net Debt to EBITDA	-3.67	4.32	5.11
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.31	-0.30	-0.04
Net Debt to NOPAT	-6.55	4.82	3.29
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	7.54	3.38	1.86
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	8.67	7.33	9.81
Quick Ratio	7.82	6.65	8.60
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	100	-224	-200
Operating Cash Flow to CapEx	392.53%	-57.02%	-138.47%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.34	0.03	0.02
Accounts Receivable Turnover	4.87	1.10	0.90
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	74.88	332.04	406.40
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	74.88	332.04	406.40
Capital & Investment Metrics	-	-	-
Invested Capital	293	351	331
Invested Capital Turnover	1.79	0.12	0.08
Increase / (Decrease) in Invested Capital	43	58	-20
Enterprise Value (EV)	1,958	856	141
Market Capitalization	2,898	1,657	865
Book Value per Share	$4.31	$3.97	$3.58
Tangible Book Value per Share	$3.68	$3.39	$3.27
Total Capital	1,277	1,203	1,064
Total Debt	44	50	8.09
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-940	-801	-725
Capital Expenditures (CapEx)	71	77	78
Debt-free, Cash-free Net Working Capital (DFCFNWC)	40	18	32
Debt-free Net Working Capital (DFNWC)	951	803	683
Net Working Capital (NWC)	907	753	675
Net Nonoperating Expense (NNE)	-15	-20	-57
Net Nonoperating Obligations (NNO)	-940	-801	-725
Total Depreciation and Amortization (D&A)	33	31	97
Debt-free, Cash-free Net Working Capital to Revenue	8.22%	46.97%	111.79%
Debt-free Net Working Capital to Revenue	195.99%	2,112.94%	2,368.28%
Net Working Capital to Revenue	186.88%	1,980.20%	2,340.23%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.56	($0.51)	($0.55)
Adjusted Weighted Average Basic Shares Outstanding	285.06M	289.17M	294.33M
Adjusted Diluted Earnings per Share	$0.50	($0.51)	($0.55)
Adjusted Weighted Average Diluted Shares Outstanding	314.83M	289.17M	294.33M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	287.69M	292.78M	297.99M
Normalized Net Operating Profit after Tax (NOPAT)	144	-166	-220
Normalized NOPAT Margin	29.57%	-436.67%	-764.18%
Pre Tax Income Margin	49.26%	-457.67%	-695.02%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from AbCellera Biologics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	1,740.65%	-84.54%	-96.15%	-78.10%	-93.49%	-57.40%	-18.36%	-27.18%	-1.39%	-44.99%
EBITDA Growth	329.99%	-128.40%	-121.60%	-1,738.29%	-189.21%	-106.01%	8.67%	51.96%	20.34%	17.57%
EBIT Growth	264.31%	-148.98%	-125.16%	-487.75%	-221.90%	-49.47%	8.22%	-18.87%	-44.42%	6.84%
NOPAT Growth	209.65%	-145.87%	-127.64%	-512.07%	-278.17%	-74.85%	15.38%	-81.86%	-70.64%	-10.14%
Net Income Growth	224.53%	-149.87%	-123.79%	-349.93%	-207.46%	-57.73%	-1.25%	-20.97%	-78.63%	27.44%
EPS Growth	200.00%	-150.00%	-125.93%	-450.00%	-225.00%	-60.00%	0.00%	-18.18%	-70.00%	31.25%
Operating Cash Flow Growth	-2,037.32%	284.97%	-143.97%	-92.71%	99.92%	-163.44%	5.34%	-250.56%	-27,147.17%	59.21%
Free Cash Flow Firm Growth	25.80%	-283.83%	-200.98%	-6,769.53%	42.48%	-49.57%	-0.41%	79.87%	38.09%	70.28%
Invested Capital Growth	96.18%	17.22%	1.98%	176.24%	12.45%	19.69%	3.88%	-2.87%	-4.65%	-5.70%
Revenue Q/Q Growth	120.80%	-78.75%	-43.41%	-17.52%	-34.38%	39.08%	8.46%	-26.43%	-11.14%	-22.41%
EBITDA Q/Q Growth	2,214.17%	-151.29%	-107.34%	18.23%	-2.60%	-18.43%	8.08%	56.99%	-70.12%	-22.56%
EBIT Q/Q Growth	594.35%	-197.13%	-45.29%	15.76%	-2.53%	-19.10%	10.78%	-9.11%	-24.57%	23.17%
NOPAT Q/Q Growth	466.93%	-222.63%	-71.72%	20.79%	-6.81%	-20.34%	16.90%	-70.24%	-0.22%	22.32%
Net Income Q/Q Growth	492.40%	-212.28%	-34.18%	23.89%	6.28%	-64.80%	13.87%	9.06%	-38.39%	33.06%
EPS Q/Q Growth	500.00%	-225.00%	-40.00%	21.43%	9.09%	-60.00%	12.50%	7.14%	-30.77%	35.29%
Operating Cash Flow Q/Q Growth	-146.44%	124.38%	-242.54%	145.17%	-100.53%	-18,400.94%	-112.68%	28.15%	3.62%	72.30%
Free Cash Flow Firm Q/Q Growth	-3,449.36%	49.12%	24.31%	-417.05%	71.11%	-32.31%	49.19%	-3.63%	11.14%	36.48%
Invested Capital Q/Q Growth	140.85%	-9.08%	26.86%	-0.56%	-1.96%	-3.23%	10.09%	-7.02%	-3.75%	-4.28%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	47.11%	-113.70%	-416.56%	-412.96%	-645.66%	-549.80%	-465.96%	-272.44%	-521.59%	-823.87%
Operating Margin	37.22%	-175.36%	-532.10%	-511.03%	-831.79%	-719.70%	-551.48%	-1,276.17%	-1,439.42%	-1,440.98%
EBIT Margin	40.47%	-185.00%	-474.96%	-485.11%	-757.93%	-649.05%	-533.94%	-791.86%	-1,110.11%	-1,099.17%
Profit (Net Income) Margin	26.26%	-138.76%	-328.99%	-303.58%	-433.55%	-513.73%	-407.98%	-504.30%	-785.42%	-677.56%
Tax Burden Percent	57.15%	95.17%	83.31%	80.33%	72.84%	97.01%	95.00%	76.64%	81.60%	73.05%
Interest Burden Percent	113.54%	78.81%	83.15%	77.90%	78.53%	81.59%	80.43%	83.10%	86.71%	84.38%
Effective Tax Rate	42.85%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	52.66%	-219.13%	-182.89%	-205.98%	-85.57%	-59.42%	-36.40%	-80.92%	-93.68%	-85.22%
ROIC Less NNEP Spread (ROIC-NNEP)	52.07%	-218.73%	-183.53%	-206.56%	-86.69%	-59.32%	-36.13%	-84.54%	-95.54%	-87.41%
Return on Net Nonoperating Assets (RNNOA)	-40.55%	166.07%	127.51%	163.30%	62.26%	43.29%	24.40%	57.78%	65.58%	60.40%
Return on Equity (ROE)	12.10%	-53.06%	-55.38%	-42.69%	-23.31%	-16.14%	-12.00%	-23.14%	-28.10%	-24.82%
Cash Return on Invested Capital (CROIC)	31.40%	36.94%	-15.88%	-125.98%	-54.38%	-69.43%	-45.71%	-48.74%	-56.06%	-58.70%
Operating Return on Assets (OROA)	17.92%	-62.81%	-55.65%	-44.99%	-24.92%	-16.30%	-12.91%	-17.75%	-25.19%	-22.25%
Return on Assets (ROA)	11.63%	-47.11%	-38.55%	-28.15%	-14.26%	-12.90%	-9.86%	-11.30%	-17.82%	-13.72%
Return on Common Equity (ROCE)	12.10%	-53.06%	-55.38%	-42.69%	-23.31%	-16.14%	-12.00%	-23.14%	-28.10%	-24.82%
Return on Equity Simple (ROE_SIMPLE)	19.87%	0.00%	-4.15%	-6.19%	-10.92%	0.00%	-13.00%	-13.80%	-16.31%	0.00%
Net Operating Profit after Tax (NOPAT)	22	-26	-45	-36	-38	-46	-38	-65	-66	-51
NOPAT Margin	21.27%	-122.75%	-372.47%	-357.72%	-582.25%	-503.79%	-386.03%	-893.32%	-1,007.59%	-1,008.68%
Net Nonoperating Expense Percent (NNEP)	0.59%	-0.40%	0.63%	0.57%	1.12%	-0.10%	-0.28%	3.62%	1.86%	2.19%
Return On Investment Capital (ROIC_SIMPLE)	-	-2.07%	-	-	-	-3.84%	-	-	-	-4.79%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	13.60%	60.40%	124.13%	154.35%	217.75%	174.06%	174.32%	275.73%	294.25%	317.29%
R&D to Revenue	26.22%	131.11%	431.82%	362.70%	574.59%	529.76%	394.69%	558.88%	629.61%	912.58%
Operating Expenses to Revenue	62.78%	275.36%	632.10%	611.03%	931.79%	819.70%	651.48%	1,376.17%	1,539.42%	1,540.98%
Earnings before Interest and Taxes (EBIT)	41	-40	-58	-49	-50	-60	-53	-58	-72	-55
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	48	-24	-51	-42	-43	-50	-46	-20	-34	-42
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.26	2.35	1.79	1.56	1.13	1.44	1.16	0.78	0.71	0.82
Price to Tangible Book Value (P/TBV)	2.66	2.75	2.10	1.83	1.32	1.68	1.36	0.89	0.78	0.90
Price to Revenue (P/Rev)	4.68	5.97	11.98	12.85	26.41	43.57	36.73	26.33	23.24	30.02
Price to Earnings (P/E)	11.35	18.28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	8.81%	5.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	5.86	6.67	3.58	2.81	1.41	2.44	1.48	0.33	0.10	0.42
Enterprise Value to Revenue (EV/Rev)	3.14	4.03	7.36	7.17	10.15	22.51	15.96	3.60	1.04	4.88
Enterprise Value to EBITDA (EV/EBITDA)	5.16	7.65	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	5.50	8.78	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	8.06	13.64	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	8.24	7.06	10.02	0.00	76.92	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	24.74	19.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.03	0.04	0.04	0.05	0.05	0.04	0.05	0.02	0.02	0.01
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.78	-0.76	-0.69	-0.79	-0.72	-0.73	-0.68	-0.68	-0.69	-0.69
Leverage Ratio	1.24	1.27	1.28	1.30	1.26	1.27	1.27	1.28	1.28	1.29
Compound Leverage Factor	1.40	1.00	1.06	1.01	0.99	1.04	1.02	1.06	1.11	1.09
Debt to Total Capital	2.54%	3.46%	3.43%	4.39%	4.36%	4.20%	4.35%	1.77%	1.84%	0.76%
Short-Term Debt to Total Capital	2.54%	3.46%	3.43%	4.39%	4.36%	4.20%	4.35%	1.77%	1.84%	0.76%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	97.46%	96.54%	96.57%	95.61%	95.64%	95.80%	95.65%	98.23%	98.16%	99.24%
Debt to EBITDA	0.09	0.17	-1.44	-0.79	-0.34	-0.27	-0.28	-0.13	-0.13	-0.06
Net Debt to EBITDA	-2.53	-3.67	28.08	11.94	5.14	4.32	4.11	4.71	4.86	5.11
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.14	0.31	-0.84	-0.67	-0.37	-0.30	-0.32	-0.11	-0.09	-0.04
Net Debt to NOPAT	-3.95	-6.55	16.29	10.13	5.61	4.82	4.67	3.99	3.39	3.29
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	7.21	6.98	5.53	4.22	3.29	3.72	3.08	2.42	2.04	2.31
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.86	8.67	10.50	7.83	8.34	7.33	7.76	10.96	9.34	9.81
Quick Ratio	9.19	7.82	9.11	7.08	7.47	6.65	6.98	10.04	8.48	8.60
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-137	-70	-53	-272	-79	-104	-53	-55	-49	-31
Operating Cash Flow to CapEx	-1,013.23%	250.71%	-294.07%	73.17%	-0.52%	-135.89%	-172.78%	-149.01%	-155.98%	-51.18%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.44	0.34	0.12	0.09	0.03	0.03	0.02	0.02	0.02	0.02
Accounts Receivable Turnover	8.06	4.87	1.02	2.95	0.70	1.10	1.32	0.81	0.96	0.90
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	4.13	0.00	1.02	0.71	0.21	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	45.26	74.88	357.27	123.79	519.40	332.04	277.53	451.76	381.03	406.40
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	45.26	74.88	357.27	123.79	519.40	332.04	277.53	451.76	381.03	406.40
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	323	293	372	370	363	351	387	360	346	331
Invested Capital Turnover	2.48	1.79	0.49	0.58	0.15	0.12	0.09	0.09	0.09	0.08
Increase / (Decrease) in Invested Capital	158	43	7.23	236	40	58	14	-11	-17	-20
Enterprise Value (EV)	1,893	1,958	1,333	1,041	511	856	571	119	34	141
Market Capitalization	2,820	2,898	2,169	1,865	1,331	1,657	1,314	870	766	865
Book Value per Share	$4.38	$4.31	$4.20	$4.14	$4.09	$3.97	$3.86	$3.78	$3.66	$3.58
Tangible Book Value per Share	$3.72	$3.68	$3.59	$3.53	$3.49	$3.39	$3.29	$3.32	$3.32	$3.27
Total Capital	1,283	1,277	1,251	1,250	1,237	1,203	1,181	1,131	1,098	1,064
Total Debt	33	44	43	55	54	50	51	20	20	8.09
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-927	-940	-836	-825	-820	-801	-743	-751	-732	-725
Capital Expenditures (CapEx)	13	12	15	27	20	14	24	20	19	16
Debt-free, Cash-free Net Working Capital (DFCFNWC)	79	40	72	46	52	18	37	26	15	32
Debt-free Net Working Capital (DFNWC)	972	951	894	867	863	803	760	721	684	683
Net Working Capital (NWC)	940	907	851	812	809	753	709	701	663	675
Net Nonoperating Expense (NNE)	-5.06	3.45	-5.30	-5.44	-9.81	0.91	2.18	-28	-14	-17
Net Nonoperating Obligations (NNO)	-927	-940	-836	-825	-820	-801	-743	-751	-732	-725
Total Depreciation and Amortization (D&A)	6.73	15	7.12	7.26	7.41	9.11	6.77	38	38	14
Debt-free, Cash-free Net Working Capital to Revenue	13.09%	8.22%	40.02%	31.69%	103.93%	46.97%	104.71%	78.19%	46.70%	111.79%
Debt-free Net Working Capital to Revenue	161.17%	195.99%	493.79%	597.01%	1,713.05%	2,112.94%	2,125.06%	2,181.89%	2,073.70%	2,368.28%
Net Working Capital to Revenue	155.77%	186.88%	470.11%	559.21%	1,606.03%	1,980.20%	1,981.35%	2,121.30%	2,012.36%	2,340.23%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.09	($0.10)	($0.14)	($0.11)	($0.10)	($0.16)	($0.14)	($0.13)	($0.17)	($0.11)
Adjusted Weighted Average Basic Shares Outstanding	285.32M	285.06M	287.77M	288.91M	289.50M	289.17M	292.72M	294.22M	294.85M	294.33M
Adjusted Diluted Earnings per Share	$0.08	($0.10)	($0.14)	($0.11)	($0.10)	($0.16)	($0.14)	($0.13)	($0.17)	($0.11)
Adjusted Weighted Average Diluted Shares Outstanding	315.82M	314.83M	287.77M	288.91M	289.50M	289.17M	292.72M	294.22M	294.85M	294.33M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	286.10M	287.69M	288.73M	289.36M	290.17M	292.78M	294.05M	294.67M	295.37M	297.99M
Normalized Net Operating Profit after Tax (NOPAT)	22	-26	-45	-36	-38	-46	-38	-65	-66	-51
Normalized NOPAT Margin	21.27%	-122.75%	-372.47%	-357.72%	-582.25%	-503.79%	-386.03%	-893.32%	-1,007.59%	-1,008.68%
Pre Tax Income Margin	45.95%	-145.81%	-394.91%	-377.92%	-595.18%	-529.54%	-429.45%	-658.02%	-962.53%	-927.49%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About AbCellera Biologics' Financials

When does AbCellera Biologics's fiscal year end?

According to the most recent income statement we have on file, AbCellera Biologics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has AbCellera Biologics' net income changed over the last 2 years?

AbCellera Biologics' net income appears to be on an upward trend, with a most recent value of -$162.86 million in 2024, falling from $158.52 million in 2022. The previous period was -$146.40 million in 2023.

What is AbCellera Biologics's operating income?

AbCellera Biologics's total operating income in 2024 was -$314.77 million, based on the following breakdown:

Total Gross Profit: $28.83 million
Total Operating Expenses: $343.60 million

How has AbCellera Biologics revenue changed over the last 2 years?

Over the last 2 years, AbCellera Biologics' total revenue changed from $485.42 million in 2022 to $28.83 million in 2024, a change of -94.1%.

How much debt does AbCellera Biologics have?

AbCellera Biologics' total liabilities were at $304.47 million at the end of 2024, a 9.3% decrease from 2023, and a 1.0% decrease since 2022.

How much cash does AbCellera Biologics have?

In the past 2 years, AbCellera Biologics' cash and equivalents has ranged from $133.32 million in 2023 to $386.54 million in 2022, and is currently $156.33 million as of their latest financial filing in 2024.

How has AbCellera Biologics' book value per share changed over the last 2 years?

Over the last 2 years, AbCellera Biologics' book value per share changed from 4.31 in 2022 to 3.58 in 2024, a change of -17.1%.

Remove Ads

Related Companies

This page (NASDAQ:ABCL) was last updated on 4/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbCellera Biologics (ABCL) Financials

Frequently Asked Questions About AbCellera Biologics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AbCellera Biologics (ABCL) Financials

Annual Income Statements for AbCellera Biologics

Quarterly Income Statements for AbCellera Biologics

Annual Cash Flow Statements for AbCellera Biologics

Quarterly Cash Flow Statements for AbCellera Biologics

Annual Balance Sheets for AbCellera Biologics

Quarterly Balance Sheets for AbCellera Biologics

Annual Metrics and Ratios for AbCellera Biologics

Quarterly Metrics and Ratios for AbCellera Biologics

Frequently Asked Questions About AbCellera Biologics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools